Van Truong

Van Truong

Auto-generated profile, based on publicly available information

Van Truong

Institute for Biomedical Informatics, University of Pennsylvania , 3700 Hamilton Walk, 19104 Philadelphia, PA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MTMomchil S. Tomov
Momchil S. Tomov
VTVan Q. Truong
Van Q. Truong
RHRohan A. Hundia
Rohan A. Hundia
SGSamuel J. Gershman
Samuel J. Gershman
Most real-world decisions involve a delicate balance between exploring unfamiliar alternatives and committing to the best known option. Previous work has shown that humans rely on different forms of uncertainty to negotiate this "explore-exploit” trade-off, yet the neural basis of the underlying computations remains unclear. Using fMRI (n = 31), we find that relative uncertainty is represented in right rostrolateral prefrontal cortex and drives directed exploration, while total uncertainty is represented in right dorsolateral prefrontal cortex and drives random exploration. The decision value signal combining relative and total uncertainty to compute choice is reflected in motor cortex activity. The variance of this signal scales with total uncertainty, consistent with a sampling mechanism for random exploration. Overall, these results are consistent with a hybrid computational architecture in which different uncertainty computations are performed separately and then combined by downstream decision circuits to compute choice.

18 April 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Joseph D. RomanoJoseph D. Romano
Joseph D. Romano
VTVan Truong
Van Truong
RKRachit Kumar
Rachit Kumar
MVMythreye Venkatesan
Mythreye Venkatesan
BGBritney E Graham
Britney E Graham
JMJason H. Moore
Jason H. Moore
Background: As global populations age and become susceptible to neurodegenerative illnesses, new therapies for Alzheimer disease (AD) are urgently needed. Existing data resources for drug discovery and repurposing fail to capture relationships central to the disease’s etiology and response to drugs. Objective: We designed the Alzheimer’s Knowledge Base (AlzKB) to alleviate this need by providing a comprehensive knowledge representation of AD etiology and candidate therapeutics. Methods: We designed the AlzKB as a large, heterogeneous graph knowledge base assembled using 22 diverse external data sources describing biological and pharmaceutical entities at different levels of organization (eg, chemicals, genes, anatomy, and diseases). AlzKB uses a Web Ontology Language 2 ontology to enforce semantic consistency and allow for ontological inference. We provide a public version of AlzKB and allow users to run and modify local versions of the knowledge base. Results: AlzKB is freely available on the web and currently contains 118,902 entities with 1,309,527 relationships between those entities. To demonstrate its value, we used graph data science and machine learning to (1) propose new therapeutic targets based on similarities of AD to Parkinson disease and (2) repurpose existing drugs that may treat AD. For each use case, AlzKB recovers known therapeutic associations while proposing biologically plausible new ones. Conclusions: AlzKB is a new, publicly available knowledge resource that enables researchers to discover complex translational associations for AD drug discovery. Through 2 use cases, we show that it is a valuable tool for proposing novel therapeutic hypotheses based on public biomedical knowledge.

3 July 2026 in Briefings in Bioinformatics
Verified
Journal Article
Open access
VTVan Q Truong
Van Q Truong
MRMarylyn Ritchie
Marylyn Ritchie
Over the past 75 years, especially the recent quarter century, bioinformatics has undergone a profound transformation, evolving from a specialized field of command-line tools to a cornerstone of modern biomedical and life sciences. We trace this journey through distinct technological eras driven by exponential biological data growth and parallel computational advances. The genomic revolution established foundational sequence analysis tools and was rapidly followed by the next-generation sequencing era, when unprecedented data volumes shifted the bottleneck from generation to analysis. This drove the development of web servers, cloud platforms, and containerized workflows to address scalability, accessibility, and reproducibility challenges. We now stand in the artificial intelligence (AI)-driven era, where deep learning (e.g. AlphaFold series) and large language models reshape structural biology, multi-modal data integration, and how researchers interact with tools through natural language prompting. This review highlights a recurring pattern as each technological era lowers barriers to entry, it simultaneously introduces new questions about transparency, trust, and rigor. By framing the popular rise of AI within this historical context, we provide a critical roadmap for navigating the cultural, ethical, and technical crossroads facing the next generation of bioinformatics.

18 November 2026 in bioRxiv
Verified
Preprint
Open access
RSRohan Shah
Rohan Shah
SGSumita Garai
Sumita Garai
DFD. Darrell De Freitas
D. Darrell De Freitas
VTVan Qt Truong
Van Qt Truong
WGWolfgang Ganglberger
Wolfgang Ganglberger
JWJoost Wagenaar
Joost Wagenaar
Background: Biomedical time series are recorded at high sampling rates for hours to days across tens to hundreds of channels. Each recording occupies gigabytes to terabytes of storage. FAIR data sharing requirements often place recordings in cloud storage. Visual analysis requires downsampling windows wider than a few seconds to the pixel width of the screen. Visualization tools therefore either read a local copy of the recording or query a dedicated resampling server in front of the data. Findings: We present TS-Zarr, a Zarr v3 layout for time series data. It stores the samples of each channel alongside a pyramid of summary statistics at progressively coarser levels. Zarr on cloud storage offers low-latency, high-throughput parallel reads. The layout lets a reader fetch only the channels and windows it needs. These targeted reads scale better than the same reads from HDF5 and EDF. Precomputed levels trade additional storage and error-bound signal transformation for faster and more scalable visual analysis that moves from the whole recording to narrow windows. As users grow and windows widen, precomputed reads from cloud storage scale beyond the point at which a resampling server fails. Conclusions: Precomputed levels let researchers visualize a recording without downloading a local copy or querying a dedicated resampling server. The time to read a view remains bounded as the window under view widens. Zarr on cloud storage also provides efficient, highly parallelizable, targeted reads of raw sample data for analysis.

24 February 2023 in JMIR Preprints
Verified
Preprint
Open access
Joseph D. RomanoJoseph D. Romano
Joseph D. Romano
VTVan Truong
Van Truong
RKRachit Kumar
Rachit Kumar
MVMythreye Venkatesan
Mythreye Venkatesan
BGBritney E Graham
Britney E Graham
JMJason H. Moore
Jason H. Moore
BACKGROUND As global populations age and become susceptible to neurodegenerative illnesses, new therapies for Alzheimer disease (AD) are urgently needed. Existing data resources for drug discovery and repurposing fail to capture relationships central to the disease’s etiology and response to drugs. OBJECTIVE We designed the Alzheimer’s Knowledge Base (AlzKB) to alleviate this need by providing a comprehensive knowledge representation of AD etiology and candidate therapeutics. METHODS We designed the AlzKB as a large, heterogeneous graph knowledge base assembled using 22 diverse external data sources describing biological and pharmaceutical entities at different levels of organization (eg, chemicals, genes, anatomy, and diseases). AlzKB uses a Web Ontology Language 2 ontology to enforce semantic consistency and allow for ontological inference. We provide a public version of AlzKB and allow users to run and modify local versions of the knowledge base. RESULTS AlzKB is freely available on the web and currently contains 118,902 entities with 1,309,527 relationships between those entities. To demonstrate its value, we used graph data science and machine learning to (1) propose new therapeutic targets based on similarities of AD to Parkinson disease and (2) repurpose existing drugs that may treat AD. For each use case, AlzKB recovers known therapeutic associations while proposing biologically plausible new ones. CONCLUSIONS AlzKB is a new, publicly available knowledge resource that enables researchers to discover complex translational associations for AD drug discovery. Through 2 use cases, we show that it is a valuable tool for proposing novel therapeutic hypotheses based on public biomedical knowledge.